Biotechnology
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

$3.7B

Market Cap • 12/25/2024

2005

(19 years)
Founded

2017

(7 years ago)
IPO

NASDAQ

Listing Exchange
Flag of GB

London

Headquarters